BIOMAT Database Logo BIOMAT Database Logo

Renal prostacyclin influences renal function in non-azotemic cirrhotic patients treated with furosemide. 1991

J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Department of Internal Medicine, University Clinic of Navarra, Pamplona, Spain.

The influence of prostaglandins on renal function changes induced by furosemide was analyzed in 21 non-azotemic cirrhotic patients with ascites. Patients were studied in two periods of 120 min immediately before and after furosemide infusion (20 mg, ev). Furosemide caused an increase in creatinine clearance in 15 patients (group A: 99 +/- 7 vs. 129 +/- 5 ml/min; mean +/- S.E.) and a reduction in the remaining six (group B: 102 +/- 13 vs. 71 +/- 9 ml/min). Parallel changes were observed in the urinary excretion of 6-Keto-prostaglandin-F1 alpha (metabolite of renal prostacyclin) which augmented after furosemide in 14 of the 15 patients from group A (478 +/- 107 vs. 1034 +/- 159 pg/min, p less than 0.001) and decreased in all patients from group B (1032 +/- 240 vs. 548 +/- 136 pg/min, p less than 0.05). In contrast, the urinary excretion of prostaglandin E2 was stimulated by furosemide in all patients (group A, 92 +/- 19 vs. 448 +/- 60 pg/min, p less than 0.001; and group B, 209 +/- 63 vs. 361 +/- 25 pg/min, p less than 0.05). In all of the patients furosemide-induced changes (post- minus pre-furosemide values) in creatinine clearance were closely correlated in a direct and linear fashion with those in 6-Keto-prostaglandin-F1 alpha (r = 0.74; p less than 0.001). These changes were associated with a higher furosemide-induced natriuresis in group A than in group B (641 +/- 68 vs. 302 +/- 46 mumol/min, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D005260 Female Females
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014511 Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. Uremias
D015121 6-Ketoprostaglandin F1 alpha The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. 6-Keto-PGF1 alpha,6-Oxo-PGF1 alpha,6-Oxoprostaglandin F1 alpha,6 Ketoprostaglandin F1 alpha,6 Keto PGF1 alpha,6 Oxo PGF1 alpha,6 Oxoprostaglandin F1 alpha,F1 alpha, 6-Ketoprostaglandin,F1 alpha, 6-Oxoprostaglandin,alpha, 6-Keto-PGF1,alpha, 6-Ketoprostaglandin F1,alpha, 6-Oxo-PGF1,alpha, 6-Oxoprostaglandin F1
D015232 Dinoprostone The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. PGE2,PGE2alpha,Prostaglandin E2,Prostaglandin E2alpha,PGE2 alpha,Prepidil Gel,Prostaglandin E2 alpha,Prostenon,E2 alpha, Prostaglandin,E2, Prostaglandin,E2alpha, Prostaglandin,Gel, Prepidil,alpha, PGE2,alpha, Prostaglandin E2

Related Publications

J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
August 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Furosemide disposition in cirrhotic patients.
December 1981, Gastroenterology,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites.
September 1993, Journal of hepatology,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
February 2007, Journal of hepatology,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
January 1991, Contributions to nephrology,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.
October 2017, Oncotarget,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Percutaneous angioplasty for atherosclerotic renal artery disease: effect on renal function in azotemic patients.
January 1994, Cardiovascular and interventional radiology,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Hepatitis B and renal function: A matched study comparing non-hepatitis B, untreated, treated and cirrhotic hepatitis patients.
April 2019, Liver international : official journal of the International Association for the Study of the Liver,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Differential effect of CCl4 on renal function in cirrhotic and non-cirrhotic rats.
May 1999, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie,
J Quiroga, and J M Zozaya, and P Labarga, and C M Rodríguez-Ortigosa, and A Milazzo, and J Prieto
Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites.
January 2001, Transactions of the American Clinical and Climatological Association,
Copied contents to your clipboard!